Swiss Biotech Stock Poised for 100% Gain, Experts Say

Experts are optimistic about the future of Swiss biotech firm Kuros Biosciences, anticipating substantial gains for its stock. After undergoing a significant correction, the company's shares are poised for a rebound, with some analysts projecting up to a 100% increase in value.

Kuros Biosciences, a spin-off from ETH Zurich, specializes in developing and marketing orthobiologics – biological materials used in orthopedic treatments. Their flagship product, MagnetOs, stimulates the body's natural ability to regenerate bone tissue, aiding in the healing of damaged or missing bone structures. Initially used for spinal stabilization, MagnetOs is now also applied to fractures in limbs. The company also produces a sealant for tissue sealing, particularly after neurosurgical procedures on the skull.

The company has shown strong financial performance, achieving operational profit for the first time in the first half of 2025. The current year began robustly, with first-quarter revenue reaching $43.4 million, a 51% increase compared to the previous year. Production is also set to commence at a new U.S. facility in Georgia in the latter half of the year.

Analysts are largely positive, with all four listed by Bloomberg recommending a buy. They collectively see an average upside potential of 64% to 32.50 Swiss francs per share. Kepler Cheuvreux, an analysis firm, even suggests the possibility of the stock doubling. The share price experienced a surge from 1.2 to 31.6 francs between early 2023 and late 2025, before correcting to 17.8 francs. It is currently trading at 19.80 francs, with experts believing a bottom has formed.